Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -25.38% | 121.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -25.38% | 121.84% | |||
| Cost of Revenue | 1,869.23% | 188.89% | |||
| Gross Profit | -139.68% | 118.78% | |||
| SG&A Expenses | -5.91% | 9.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.88% | 2.85% | |||
| Operating Income | 15.80% | -2.38% | |||
| Income Before Tax | 5.66% | -1.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.66% | -1.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.66% | -1.36% | |||
| EBIT | 15.80% | -2.38% | |||
| EBITDA | 15.82% | -2.38% | |||
| EPS Basic | 5.92% | 0.62% | |||
| Normalized Basic EPS | 13.68% | 0.62% | |||
| EPS Diluted | 5.92% | 0.62% | |||
| Normalized Diluted EPS | 13.68% | 0.62% | |||
| Average Basic Shares Outstanding | 0.28% | 2.00% | |||
| Average Diluted Shares Outstanding | 0.28% | 2.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||